Can this FTSE 250 underperformer turn things around in 2025?

After underperforming since its IPO, shares in Dr Martens have finally started to show some life. Is 2025 the year the FTSE 250 stock turns things around?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 250 boot manufacturer Dr Martens (LSE:DOCS) have fallen 83% since the company joined the stock market in 2021. But the stock has been showing signs of life recently.

Created with Highcharts 11.4.3Dr. Martens Plc PriceZoom1M3M6MYTD1Y5Y10YALL4 Jan 20204 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

The share price rallied sharply at the end of last year. And with a new CEO set to take charge this month, could 2025 be a year of recovery for the business?

The problems

Dr Martens has been dealing with two problems. The first is weak demand in the US and the second is difficulties with shifting from selling via retailers to selling directly to consumers.

Should you invest £1,000 in Barclays right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Barclays made the list?

See the 6 stocks

The aim has been to boost margins, but the only thing that has been going up is the firm’s costs. Managing inventory has been a challenge and this is reflected in the company’s balance sheet.

These difficulties are familiar. Nike has been having the same problems, which is why its share price has fallen since the start of 2022. 

Created with Highcharts 11.4.3Nike PriceZoom1M3M6MYTD1Y5Y10YALL21 Dec 201921 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

Dr Martens, however, has been working to address both issues. While it can’t do much about the consumer environment, it has been revamping its marketing strategy to boost demand.

The business has also been pulling back on its purchasing to bring down its inventory levels. And its net debt has fallen by 27% over the last 12 months as a result. 

In short, positive signs are starting to appear in the company’s plans to reinvigorate itself. The stock has started climbing as a result, but is this a false dawn or is there more to come in 2025?

Outlook

In terms of forecasting a recovery for Dr Martens shares in 2025, there are two questions. The first is what the business is going to do and the second is how investors will react to this. 

While the firm has done a good job with its balance sheet and its costs, it’s losing money. And while the dividend has been reduced, even this might be unsustainable unless things change.

The problem is sales – the latest update reported revenues down 18% and this is going to have to change for the stock to be a viable investment. But 2025 could be a challenging year on this front.

The threat of tariffs on imported goods in the US looks like the kind of thing that could dampen consumer demand. And that will make arresting the declining sales a challenge.

I’m therefore wary about the outlook for Dr Martens shares in 2025. Exactly how investors will react to the company’s news is hard to predict, but the business has a long way to go. 

The longer it takes for the firm’s problems to resolve, the more the stock looks like a value trap. And to some extent, this is out of the company’s hands. 

A 2025 recovery?

Sometimes, the best time to buy shares can be when it looks like everything is going wrong. Any sign of improvement can cause the share price to surge.

If signs of recovery aren’t forthcoming, though, a stock can turn out to be a value trap. Even if it recovers eventually, the cost of waiting makes it a bad investment. 

The next thing for Dr Martens is a recovery in sales. But without a strong reason for thinking this is imminent, I’m not backing this one for a 2025 comeback.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Barclays right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Barclays made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended Nike. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »